ストックスクリーナーアプリを入手
11.03
2.29%
-0.30
前日終値:
$11.33
開ける：
$11.39
24時間の取引高:
17,438
Relative Volume:
0.16
時価総額：
$384.42M
収益：
$7,000
当期純損益:
$-41.54M
株価収益率:
-11.87
EPS:
-0.929
ネットキャッシュフロー:
$-20.57M
1週間 パフォーマンス:
+2.41%
1か月 パフォーマンス:
-3.66%
6か月 パフォーマンス:
-10.80%
1年 パフォーマンス:
-29.71%
1日の値動き範囲:
$10.92
$11.44
1週間の範囲:
$10.00
$11.71
52週間の値動き範囲:
$9.85
$16.76
Benitec Biopharma Inc Stock (BNTC) Company Profile
Compare BNTC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.19 | 389.23M | 7,000 | -41.54M | -20.57M | -0.929 |
VRTX
Vertex Pharmaceuticals Inc
|
449.05 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.75 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
879.33 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.22 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.11 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-07 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-09-12 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Piper Sandler | Overweight |
| 2020-10-05 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-02-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-12-31 | 繰り返されました | Maxim Group | Buy |
| 2015-09-16 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Benitec Biopharma Inc (BNTC) 最新ニュース
Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty - GuruFocus
Guggenheim Downgrades Benitec Biopharma(BNTC.US) to Hold Rating - Moomoo
The Technical Signals Behind (BNTC) That Institutions Follow - Stock Traders Daily
BNTC Stock Price, Quote & Chart - ChartMill
Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical SupportChannel Breakout - newsline.com
Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term OutlookGamma Flip Level - The Legal Advocate
Benitec Biopharma Announces Board Changes and New Director - The Globe and Mail
Benitec BiopharmaCFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 - marketscreener.com
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role - Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones - Stock Traders Daily
Benitec Biopharma (BNTC) Edges Higher Amid Steady TradingGolden Cross - The Legal Advocate
H.C. Wainwright Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - Sahm
Benitec Biopharma Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Company Overview - minichart.com.sg
Benitec Biopharma Reports Q3 2026 Results: Strong BB-301 Clinical Progress for OPMD, $184.8M in Cash, Upcoming FDA Milestones - Minichart
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Benitec Biopharma (BNTC) Fairly Valued After Q3 FY2026 Earnin - GuruFocus
Benitec Biopharma 3Q Loss/Shr 24c >BNTC - Moomoo
Benitec Biopharma Inc. Q3 2026: Revenue $0 Net loss $(11.9M), EPS $(0.24) — 10-Q Summary - TradingView
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
Benitec Biopharma (NASDAQ: BNTC) raises $100M to fund OPMD gene therapy BB-301 - Stock Titan
Benitec Biopharma Q3 net loss narrows as expenses fall - TradingView
BB-301 data, strong cash position shape Benitec (NASDAQ: BNTC) Q3 2026 - Stock Titan
BRIEF-Benitec Biopharma Q3 Operating Income USD -13.6 Million - TradingView
Evercore ISI initiates Benitec BioPharma stock coverage at outperform By Investing.com - Investing.com Australia
BNTC Initiates Coverage On Benitec Biopharma -- Rating Set to Ou - GuruFocus
Evercore ISI initiates Benitec BioPharma stock coverage at outperform - Investing.com UK
The scenario planning at Benitec (BNTC) | Q1 2026: Earnings Fall ShortSecondary Offering - Newser
The one metric that defines Benitec (BNTC) success (On the Radar) 2026-05-08Revenue Weighted - The Legal Advocate
Trading the Move, Not the Narrative: (BNTC) Edition - Stock Traders Daily
Benitec presents OPMD gene therapy data at May conference - Investing.com UK
Benitec presents OPMD gene therapy data at May conference By Investing.com - Investing.com India
Rare swallowing disease study posts 24-month follow-up at gene therapy meeting - Stock Titan
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - ChartMill
Biotech founder behind a $14.6B sale joins Seaport board - Stock Titan
Biotech founder behind $14.6B sale joins Seaport board - Stock Titan
(BNTC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Benitec (BNTC) Stock: Why Analysts Watch It (Breakout Watch) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
Benitec Biopharma Inc (BNTC) 財務データ
収益
当期純利益
現金流量
EPS
Benitec Biopharma Inc (BNTC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
2.40%
0.80%
大文字化:
|
ボリューム (24 時間):